HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anouti, A. Articles by Koller, W.C. Search for Related Content PubMed PubMed Citation Articles by Anouti, A. Articles by Koller, W.C.

Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy

From the Department of Neurology (Drs. Anouti, Lyons, Hubble, and Koller, and K. Schmidt), University of Kansas Medical Center, Kansas City, KS; the Gerontology Research Education and Clinical Center (Dr. Schellenberg), Seattle Veterans Affairs Medical Center, Seattle, WA; the Department of Neurology (Dr. Golbe), UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ; the Division of Neurology (Drs. Lang and Galvez-Jimenez), The Toronto Hospital, 339 Bathurst Street MP11-304, Toronto, Canada; and the Neurology Service (Dr. Hershey), Buffalo Veterans Affairs Medical Center, Buffalo, NY.
Received June 22, 1995. Accepted in final form September 19, 1995.
Address correspondence and reprint requests to Dr. William C. Koller, Department of Neurology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160-7314.

Apolipoprotein E (Apo E) genotype is a genetic risk factor influencing the development of Alzheimer's disease (AD).Progressive supranuclear palsy (PSP), like AD, is a dementing illness with neurofibrillary tangles. We determined the frequencies of Apo E alleles in 52 PSP patients and 52 age- and gender-matched controls. The distribution of Apo E allele frequencies and genotypes showed no difference between PSP and controls. Apo E allele status does not influence the development of PSP.

NEUROLOGY 1996;46: 1156-1157

This article has been cited by other articles:

				K. A. Josephs, Y. Tsuboi, N. Cookson, H. Watt, and D. W. Dickson Apolipoprotein E {varepsilon}4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Arch Neurol, October 1, 2004; 61(10): 1579 - 1584. [Abstract] [Full Text] [PDF]

				Y. Tsuboi, K. A. Josephs, N. Cookson, and D. W. Dickson APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy Neurology, January 28, 2003; 60(2): 240 - 245. [Abstract] [Full Text] [PDF]

				H R Morris, J C Janssen, O Bandmann, S E Daniel, M N Rossor, A J Lees, and N W Wood The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases J. Neurol. Neurosurg. Psychiatry, May 1, 1999; 66(5): 665 - 667. [Abstract] [Full Text]

				R. Oliva, E. Tolosa, M. Ezquerra, J. L. Molinuevo, F. Valldeoriola, J. Burguera, M. Calopa, M. Villa, and F. Ballesta Significant Changes in the Tau A0 and A3 Alleles in Progressive Supranuclear Palsy and Improved Genotyping by Silver Detection Arch Neurol, August 1, 1998; 55(8): 1122 - 1124. [Abstract] [Full Text] [PDF]

				I. Litvan and A. M. Saunders Apolipoprotein E{epsilon}4 (Epsilon) Allele Does Not Affect the Onset or Symptom Severity in Progressive Supranuclear Palsy Arch Neurol, May 1, 1998; 55(5): 752 - 754. [Full Text] [PDF]